Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 12/20 | 0.34 |
| ▸ | DRD3 | P35462 | 12/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GPR6 | P46095 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16091552 | 1.00 | MAPK1 (0.34) | MAPK1DRD2DRD3KDM4EGAA | |
| SCHEMBL30790692 | 1.00 | MAPK1 (0.34) | MAPK1DRD2DRD3KDM4EGAA | |
| SCHEMBL16079665 | 0.96 | MAPK1 (0.34) | MAPK1DRD2DRD3KDM4EGAA | |
| SCHEMBL17750693 | 0.88 | DRD2 (0.35) | MAPK1DRD2DRD3KDM4EGAA | |
| SCHEMBL16040755 | 0.85 | MAPK1 (0.43) | MAPK1DRD2DRD3GPR6 | |
| SCHEMBL16079599 | 0.85 | MAPK1 (0.43) | MAPK1DRD2DRD3GPR6 | |
| SCHEMBL30790689 | 0.85 | MAPK1 (0.43) | MAPK1DRD2DRD3GPR6 | |
| SCHEMBL16040749 | 0.85 | MAPK1 (0.43) | MAPK1DRD2DRD3GPR6 | |
| SCHEMBL16088307 | 0.83 | — | — | |
| SCHEMBL16038800 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12251387-B2 | Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-03-18 | — | — | US | disclosed |
| EP-3740479-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12121524-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-22 | — | — | US | disclosed |
| US-20230277547-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3985003-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3985003-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20210236505-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-08-05 | — | — | US | disclosed |
| US-10973830-B2 | Substituted quinoxaline DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-04-13 | — | — | US | disclosed |
| US-20210060028-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-03-04 | — | — | US | disclosed |
| US-20190290654-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-26 | — | — | US | disclosed |
| EP-3527563-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-2970218-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20180311254-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-11-01 | — | — | US | disclosed |
| US-9987284-B2 | Substituted benzooxadiazole DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-05 | — | — | US | disclosed |
| US-20160340341-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-24 | — | — | US | disclosed |
| US-9340557-B2 | Substituted quinoxaline DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2970218-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014159690-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275024-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973830-B2 | Substituted quinoxaline DNA-PK inhibitors | TOP1, TOP2A, TOP2B | MAPK1 1222/4885DRD2 4728/4885DRD3 4682/4885 |
| US-20230277547-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | DTYMK, POLK, TOP1 | MAPK1 1967/4885DRD2 4736/4885DRD3 4697/4885 |
| US-20180311254-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | MAPK1 1351/4885DRD2 4882/4885DRD3 4864/4885 |
| US-20190290654-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | MAPK1 1351/4885DRD2 4882/4885DRD3 4864/4885 |
| US-12121524-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | MAPK1 1217/4885DRD2 4882/4885DRD3 4867/4885 |
| US-20160340341-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | MAPK1 1351/4885DRD2 4882/4885DRD3 4864/4885 |
| US-20210060028-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | MAPK1 1217/4885DRD2 4882/4885DRD3 4867/4885 |
| US-20140275024-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | MAPK1 1351/4885DRD2 4882/4885DRD3 4864/4885 |
| US-12251387-B2 | Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors | TOP1, TOP2A, TOP2B | MAPK1 1104/4885DRD2 4111/4885DRD3 3612/4885 |
| US-20210236505-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | DTYMK, POLK, TOP1 | MAPK1 1967/4885DRD2 4736/4885DRD3 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.